Search hospitals

>

California

>

Roseville

The Permanente Medical Group-Roseville Radiation Oncology

Claim this profile

Roseville, California 95678

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Non-Small Cell Lung Cancer

Conducts research for Breast cancer

Conducts research for Prostate Cancer

87 reported clinical trials

7 medical researchers

Photo of The Permanente Medical Group-Roseville Radiation Oncology in RosevillePhoto of The Permanente Medical Group-Roseville Radiation Oncology in RosevillePhoto of The Permanente Medical Group-Roseville Radiation Oncology in Roseville

Summary

The Permanente Medical Group-Roseville Radiation Oncology is a medical facility located in Roseville, California. This center is recognized for care of Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Breast cancer, Prostate Cancer and other specialties. The Permanente Medical Group-Roseville Radiation Oncology is involved with conducting 87 clinical trials across 146 conditions. There are 7 research doctors associated with this hospital, such as Jennifer M. Suga, Samantha A. Seaward, Tatjana Kolevska, MD, and Natalya Greyz-Yusupov.

Area of expertise

1

Breast Cancer

Global Leader

The Permanente Medical Group-Roseville Radiation Oncology has run 17 trials for Breast Cancer. Some of their research focus areas include:

HER2 positive
Stage I
Stage II
2

Lung Cancer

Global Leader

The Permanente Medical Group-Roseville Radiation Oncology has run 15 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage I

Top PIs

Clinical Trials running at The Permanente Medical Group-Roseville Radiation Oncology

Breast Cancer

Lung Cancer

Ovarian Cancer

Prostate Cancer

Cutaneous Melanoma

Brain Tumor

Esophageal cancer

Melanoma

Non-Small Cell Lung Cancer

Cardiotoxicity

Image of trial facility.

Radiation and HER2-Targeted Therapy

for Breast Cancer

This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.

Recruiting

2 awards

Phase 3

15 criteria

Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are being observed for cardiac toxicity. The largest cohort (currently open to accrual) is observational, and contains patients who are taking a beta blocker, ACE inhibitor, or ARB as well as their trastuzumab-based treatment. The goal is to understand how common cardiac problems are in this group of patients at high risk. The smaller cohort (currently closed to accrual) is randomized. Patients in this second cohort are randomized to either carvedilol or no treatment, with the goal of seeing whether carvedilol (used to treat heart failure and high blood pressure) may prevent the heart from side effects of chemotherapy.

Recruiting

2 awards

Phase 3

23 criteria

Image of trial facility.

Omitting Radiation Therapy

for Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.

Recruiting

2 awards

Phase 3

19 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at The Permanente Medical Group-Roseville Radiation Oncology?